‌

Acrigen Biosciences, Inc. SBIR Phase I Award, August 2020

A SBIR Phase I contract was awarded to Acrigen Biosciences in August, 2020 for $225,000.0 USD from the National Science Foundation.

Overview Structured Data Issues Contributors

sbir.gov/node/1839985

Is a

SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient

Acrigen Biosciences

Government Agency

National Science Foundation

Award Type

SBIR0

Contract Number (US Government)

20151480

Award Phase

Phase I0

Award Amount (USD)

225,0000

Date Awarded

August 15, 2020

End Date

January 31, 2021

Abstract

The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to enable safe and effective human gene editing, providing therapies targeting myriad human genetic diseases. CRISPR (clustered, regularly interspaced, short palindrom